Cargando…
Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report
We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cyto...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233787/ https://www.ncbi.nlm.nih.gov/pubmed/34204223 http://dx.doi.org/10.3390/ijms22126480 |
_version_ | 1783713930532618240 |
---|---|
author | Stäuble, Céline K. Lampert, Markus L. Mikoteit, Thorsten Hatzinger, Martin Hersberger, Kurt E. Meyer zu Schwabedissen, Henriette E. |
author_facet | Stäuble, Céline K. Lampert, Markus L. Mikoteit, Thorsten Hatzinger, Martin Hersberger, Kurt E. Meyer zu Schwabedissen, Henriette E. |
author_sort | Stäuble, Céline K. |
collection | PubMed |
description | We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient’s pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine. |
format | Online Article Text |
id | pubmed-8233787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82337872021-06-27 Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report Stäuble, Céline K. Lampert, Markus L. Mikoteit, Thorsten Hatzinger, Martin Hersberger, Kurt E. Meyer zu Schwabedissen, Henriette E. Int J Mol Sci Case Report We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient’s pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine. MDPI 2021-06-17 /pmc/articles/PMC8233787/ /pubmed/34204223 http://dx.doi.org/10.3390/ijms22126480 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Stäuble, Céline K. Lampert, Markus L. Mikoteit, Thorsten Hatzinger, Martin Hersberger, Kurt E. Meyer zu Schwabedissen, Henriette E. Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report |
title | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report |
title_full | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report |
title_fullStr | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report |
title_full_unstemmed | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report |
title_short | Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report |
title_sort | severe adverse drug reactions to quetiapine in two patients carrying cyp2d6*4 variants: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233787/ https://www.ncbi.nlm.nih.gov/pubmed/34204223 http://dx.doi.org/10.3390/ijms22126480 |
work_keys_str_mv | AT staublecelinek severeadversedrugreactionstoquetiapineintwopatientscarryingcyp2d64variantsacasereport AT lampertmarkusl severeadversedrugreactionstoquetiapineintwopatientscarryingcyp2d64variantsacasereport AT mikoteitthorsten severeadversedrugreactionstoquetiapineintwopatientscarryingcyp2d64variantsacasereport AT hatzingermartin severeadversedrugreactionstoquetiapineintwopatientscarryingcyp2d64variantsacasereport AT hersbergerkurte severeadversedrugreactionstoquetiapineintwopatientscarryingcyp2d64variantsacasereport AT meyerzuschwabedissenhenriettee severeadversedrugreactionstoquetiapineintwopatientscarryingcyp2d64variantsacasereport |